Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company.
Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca
Latest presentations
Q1 2025 results
We have
194
projects in our pipeline
